Danielle Curcio

1.4k citations

13 papers · 939 indexed · 2 hit papers · h-index 6

Impact in

Endocrinology, Diabetes and Metabolism top 5%
- Diabetes, Cardiovascular Risks, and Lipoproteins
Surgery top 5%
- Lipoproteins and Cardiovascular Health

Papers in

Surgery 10
- Lipoproteins and Cardiovascular Health 9
- Cholesterol and Lipid Metabolism 2
Computational Theory and Mathematics 3
- Computational Drug Discovery Methods 3

Co-authors: John J.P. Kastelein David Kallend Mark Jaros Traci Turner R. Scott Wright Lawrence A. Leiter Peter Wijngaard Frederick J. Raal
Journals: Journal of the American College of Cardiology (2 papers)Journal of clinical lipidology (2 papers)Nature Medicine (1 paper)The Journal of Prevention of Alzheimer s Disease (1 paper)Lipids in Health and Disease (1 paper)
Partner nations: United States Australia Netherlands

In The Last Decade

Danielle Curcio

13 papers receiving 907 citations

Hit Papers

align trajectories log scale

Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial 2022 · 113 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2022 Nature Medicine
2020 New England Journal of Medicine

Peers

Countries citing papers authored by Danielle Curcio

Since Specialization

Citations

This map shows the geographic impact of Danielle Curcio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Danielle Curcio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Danielle Curcio more than expected).

Fields of papers citing papers by Danielle Curcio

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Danielle Curcio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Danielle Curcio. The network helps show where Danielle Curcio may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Danielle Curcio, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Danielle Curcio Line = papers co-authored together Danielle Curcio links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work
1	Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease The Journal of Prevention of Alzheimer s Disease ·Ilídia Ferreira, Michael Szarek, Philip Scheltens, Everard G.B. Vijverberg, Andrew Hsieh, Marc Ditmarsch, Douglas Kling, Danielle Curcio, Xinhai Kong, Kausik K. Ray, Jeffrey L. Cummings, John J.P. Kastelein	2025	1
2	Abstract 4368890: Cholesteryl Ester Transfer Protein (CETP) Inhibition with Obicetrapib Produces Substantial Reductions in LDL Particles: Pooled Analysis of BROOKLYN and BROADWAY Phase 3 Clinical Trials Circulation ·Michael Davidson, Stephen C. Nicholls, Kausik K. Ray, Marc Ditmarsch, Douglas Kling, Danielle Curcio, Warren Gay, Andrew Hsieh, John J.P. Kastelein	2025	1
3	Obicetrapib exhibits favorable physiochemical and pharmacokinetic properties compared to previous cholesteryl ester transfer protein inhibitors: An integrated summary of results from non‐human primate studies and clinical trials Pharmacology Research & Perspectives ·Stephen J. Nicholls, Adam J. Nelson, John J.P. Kastelein, Marc Ditmarsch, Andrew Hsieh, Judith Johnson, Danielle Curcio, Douglas Kling, Carol F Kirkpatrick, Michael H. Davidson	2024	3
4	SYNERGISTIC EFFECT OF OBICETRAPIB AND EZETIMIBE ON CIRCULATING LDL PARTICLES Journal of the American College of Cardiology ·Andrew Hsieh, Michael H. Davidson, Marc Ditmarsch, Christie M. Ballantyne, Douglas Kling, Danielle Curcio, Mary R. Dicklin, John J.P. Kastelein	2024	1
5	Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial Journal of clinical lipidology ·Christie M. Ballantyne, Marc Ditmarsch, John J.P. Kastelein, Adam J. Nelson, Douglas Kling, Andrew Hsieh, Danielle Curcio, Kevin C. Maki, Michael H. Davidson, Stephen J. Nicholls	2023	53
6	Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial Nature Medicine ·Stephen J. Nicholls, Marc Ditmarsch, John J.P. Kastelein, Kwee Guan Eng, Douglas Kling, Danielle Curcio, Nicholas John, Michael H. Davidson Hit paper breakdown →	2022	113
7	Obicetrapib Lowers LDL-C in Patients Taking High Intensity Statins - Results from the ROSE Clinical Trial Journal of clinical lipidology ·Marc Ditmarsch, Douglas Kling, Danielle Curcio, Nicholas Alp, John J.P. Kastelein, Michael H. Davidson	2022	4
8	Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia New England Journal of Medicine ·Frederick J. Raal, David Kallend, Kausik K. Ray, Traci Turner, Wolfgang Köenig, R. Scott Wright, Peter Wijngaard, Danielle Curcio, Mark Jaros, Lawrence A. Leiter, John J.P. Kastelein Hit paper breakdown →	2020	562
9	Inclisiran reduces LDL-cholesterol independent of genotype in subjects with heterozygous familial hypercholesterolaemia Atherosclerosis ·Frederick J. Raal, David Kallend, Kausik K. Ray, Traci Turner, Wolfgang Köenig, Robert Wright, P. Wijngaard, Danielle Curcio, Mark Jaros, Okmanov R. Ya., Ulf Landmesser, John J.P. Kastelein	2020	1
10	Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial Lipids in Health and Disease ·Richard L. Dunbar, Stephen J. Nicholls, Kevin C. Maki, Eli M. Roth, David G. Orloff, Danielle Curcio, Judith Johnson, Douglas Kling, Michael H. Davidson	2015	45
11	Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study Vascular Health and Risk Management ·Elliot Offman, 道貞広瀬, Sandy Ferber, Judith Johnson, Douglas Kling, Danielle Curcio, Michael H. Davidson	2013	71
12	A Highly Bioavailable Omega-3 Free Fatty Acid Formulation Improves the Cardiovascular Risk Profile in High-Risk, Statin-Treated Patients With Residual Hypertriglyceridemia (the ESPRIT Trial) Clinical Therapeutics ·Kevin C. Maki, David G. Orloff, Stephen J. Nicholls, Richard L. Dunbar, Eli M. Roth, Danielle Curcio, Judith Johnson, Douglas Kling, Michael H. Davidson	2013	83
13	A HIGHLY BIOAVAILABLE OMEGA-3 FREE-FATTY ACID REDUCES NON-HIGH DENSITY LIPOPROTEIN CHOLESTEROL IN HIGH-RISK PATIENTS TREATED WITH A STATIN AND RESIDUAL HYPERTRIGLYCERIDEMIA (ESPRIT TRIAL) Journal of the American College of Cardiology ·Kevin C. Maki, David G. Orloff, Stephen J. Nicholls, Richard L. Dunbar, Eli M. Roth, Danielle Curcio, Judith Johnson, Douglas Kling, Michael H. Davidson	2013	1

About Danielle Curcio

Danielle Curcio is a scholar working on Surgery, Computational Theory and Mathematics, Cardiology and Cardiovascular Medicine, Economics and Econometrics and Biochemistry, having authored 13 papers that have together received 939 indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (9 papers), Pharmaceutical Economics and Policy (4 papers), Lipid metabolism and disorders (3 papers), Computational Drug Discovery Methods (3 papers), Cholesterol and Lipid Metabolism (2 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (2 papers), Drug Transport and Resistance Mechanisms (2 papers) and Nanoparticle-Based Drug Delivery (1 paper). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (257 citations), Surgery (628 citations), Cancer Research (158 citations), Cardiology and Cardiovascular Medicine (204 citations) and Nutrition and Dietetics (136 citations). Danielle Curcio has collaborated with scholars based in United States, Australia and Netherlands. Frequent co-authors include John J.P. Kastelein, David Kallend, Mark Jaros, Traci Turner, R. Scott Wright, Lawrence A. Leiter, Peter Wijngaard, Frederick J. Raal, Kausik K. Ray and Wolfgang Köenig. Their work appears in journals such as Journal of the American College of Cardiology, Journal of clinical lipidology, Nature Medicine, The Journal of Prevention of Alzheimer s Disease and Lipids in Health and Disease.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact